• / Free eNewsletters & Magazine
  • / My Account
Home>High-Priced Sale of Consumer Business Strengthens This Big Pharma Firm's Moat

High-Priced Sale of Consumer Business Strengthens This Big Pharma Firm's Moat

Morningstar Articles

Wed, 7 May 2014

The sale to Bayer monetizes Merck's consumer unit at a strong valuation, and removes Merck from an area where it lacks scale.

Related Videos

  1. The Friday Five

    Still gas in the tank for Apple, Facebook gets mobile mojo, a possible wide - moat combination, and more.

  2. 3 Dividend Stocks That Are Good Custodians for Assets

    These wide - moat firms offer above-average payouts and will likely see higher returns during the next several years as rates rise.

  3. This Undervalued Stock Is a Global Leader

    Cost and scale advantages, as well as greater product focus in the future, are positives for this wide - moat health-care name.

  4. Why Moats Matter

    An economic moat provides a gauge of a company's competitive advantages and overall strength, and it is a highly valuable tool for investors of all levels.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.